A Phase II Study of Cetuximab/Irinotecan in Patients with Heavily Pretreated Metastatic Colorectal Cancer: Predictive Value of Early Specific Toxicities

2008 ◽  
Vol 7 (4) ◽  
pp. 273-279 ◽  
Author(s):  
Teresa Gamucci ◽  
Fabrizio Nelli ◽  
Giovanni Cianci ◽  
Giulia Grassi ◽  
Luca Moscetti ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Predictive Value ◽  
Phase Ii Study ◽  
Heavily Pretreated

A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3502-3502 ◽  
Author(s):  
M. J. Pishvaian ◽  
R. Slack ◽  
A. Witkiewicz ◽  
A. R. He ◽  
J. J. Hwang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Parp Inhibitor ◽  
Heavily Pretreated

Phase II study of a 21-day continuous infusion schedule with epirubicin in metastatic colorectal cancer

1988 ◽  
Vol 24 (4) ◽  
pp. 801-802 ◽  
Author(s):  
Janke Greidanus ◽  
Pax H.B. Willemse ◽  
Dirk Th. Sleijfer ◽  
Nanno H. Mulder ◽  
RenéC.J. Verschueren ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Infusion Schedule

A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

2014 ◽  
Vol 37 (1) ◽  
pp. 19-23 ◽  
Author(s):  
Yong Sang Hong ◽  
Sung Sook Lee ◽  
Kyu-pyo Kim ◽  
Jae-Lyun Lee ◽  
Yoon-Koo Kang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study
Sign in / Sign up

Export Citation Format

Share Document